Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00439920
Status:
UNKNOWN
Last Update Posted:
2018-10-23
First Post:
2007-02-23
Brief Title:
GIMEMA LAL 0496 High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL
Sponsor:
Gruppo Italiano Malattie EMatologiche dellAdulto
Organization:
Gruppo Italiano Malattie EMatologiche dellAdulto
Study Overview
Official Title:
GIMEMA LAL 0496 High-dose Anthracycline in the Induction Regimen for the Treatment of Adult Acute Lymphoblastic Leukemia A Prospective Multicentric GIMEMA Trial
Status:
UNKNOWN
Status Verified Date:
2018-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study aims at verifying the state of the art in what this illness concerns and at organizing a centralized samples analysis
Detailed Description:
The present trial is a prospective multicentric GIMEMA study in which adult ALL patients are extensively analyzed at diagnosis by a multiparametric approach including CC and molecular analysis for the following gene rearrangements BCR-ABL MLL-AF4 E2A-PBX1 TEL-AML1 MLL p15 and p16 deletion in order to give place to a carefully characterization of the genetic lesions occurring in adult ALL and to evaluate their prognostic significance in a large cohort of patients homogeneously treated
This study requires a central handling and analysis of bone marrow BM or peripheral blood samples at presentation
This study requires a central handling and analysis of bone marrow BM or peripheral blood samples at presentation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None